Beekman Andrew M, Howell Lesley A
School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk, NR4 7TJ, UK.
ChemMedChem. 2016 Apr 19;11(8):802-13. doi: 10.1002/cmdc.201500497. Epub 2015 Dec 23.
The ability of protein-protein interactions to regulate cellular processes in both beneficial and detrimental ways has made them obvious drug targets. The Bcl-2 family of proteins undergo a series of protein-protein interactions which regulate the intrinsic cell-death pathway. The pro-survival members of the Bcl-2 family, including Bcl-2, Bcl-xL , and Mcl-1, are commonly overexpressed in a number of human cancers. Effective modulators of members of the Bcl-2 family have been developed and are undergoing clinical trials, but the efficient modulation of Mcl-1 is still not represented in the clinic. In addition, Mcl-1 is a major cause of resistance to radio- and chemotherapies, including inhibitors that target other Bcl-2 family members. Subsequently, the inhibition of Mcl-1 has become of significant interest to the scientific community. This review covers the progress made to date in modulating the activity of Mcl-1, by both stapled peptides and small molecules. The development of peptides as drug candidates, and the advancement of experimental and computational techniques used to discover small molecules are also highlighted.
蛋白质-蛋白质相互作用以有益和有害的方式调节细胞过程的能力使其成为明显的药物靶点。Bcl-2家族蛋白经历一系列调节细胞内源性死亡途径的蛋白质-蛋白质相互作用。Bcl-2家族的促生存成员,包括Bcl-2、Bcl-xL和Mcl-1,在许多人类癌症中通常过度表达。已开发出Bcl-2家族成员的有效调节剂并正在进行临床试验,但Mcl-1的有效调节在临床上仍未实现。此外,Mcl-1是对放疗和化疗(包括靶向其他Bcl-2家族成员的抑制剂)产生耐药性的主要原因。随后,抑制Mcl-1已引起科学界的极大兴趣。本综述涵盖了迄今为止通过环肽和小分子调节Mcl-1活性所取得的进展。还强调了作为候选药物的肽的开发以及用于发现小分子的实验和计算技术的进步。